Posted in | News

Nanogen Awarded Patents for Biomarkers Associated with Diabetes, Alzheimers Disease

Nanogen has been issued four patents by the U.S. Patent and Trademark Office for inventions related to diabetes and Alzheimers disease biomarkers. The current patents are the most recent in a series describing biomarkers associated with these diseases.

U.S. Patent No. 7,179,610, “Complement C3 precursor biopolymer markers indicative of insulin resistance,” and U.S. Patent No. 7,132,244, “Betaine/GABA transport protein biopolymer marker indicative of insulin resistance,” describe the use of mass spectrometry and time-of-flight detection techniques to identify biopolymers that could potentially be used in the diagnosis of or development of therapeutics for the metabolic conditions Syndrome X and type II diabetes.

U.S. Patent No. 7,179,605, “Fibronectin precursor biopolymer markers indicative of Alzheimer’s disease,” and U.S. Patent No. 7,179,606, “IG heavy chain, IG kappa, IF lambda biopolymer markers indicative of Alzheimer’s disease,” relate to the identification of protein biomarkers for Alzheimer’s disease.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type